Dysregulation of Cellular Signaling by HER2/neu in Breast Cancer

Seminars in Oncology

Volumn 30, Issue 5 SUPPL. 16, 2003, Pages 38-48

  Zhou, Binhua P ^a   Hung, Mien Chie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P21; UNCLASSIFIED DRUG;

BREAST CARCINOMA; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONFERENCE PAPER; DNA STRAND BREAKAGE; GENE OVEREXPRESSION; HUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TRANSLATION REGULATION;

EID: 0242468905     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.08.006     Document Type: Conference Paper

References (107)

1. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001
2. Yu D, Hung MC: Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19:6115-6121, 2000
3. Carraway KL III, Weber JL, Unger MJ, et al: Neuregulin-2, a new ligand of ErbB3/ErbB4- receptor tyrosine kinases. Nature 387:512-516, 1997
4. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
5. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
6. Hou L, Shi D, Tu SM, et al: Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Cancer Lett 65:215-220, 1992
7. Schneider PM, Hung MC, Chiocca SM, et al: Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 49:4968-4971, 1989
8. Weiner DB, Nordberg J, Robinson R, et al: Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res 50:421-425, 1990
9. Yokota J, Yamamoto T, Miyajima N, et al: Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 2:283-287, 1988
10. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995
11. Harper JW, Adami GR, Wei N, et al: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816, 1993
12. el-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993
13. Noda A, Ning Y, Venable SF, et al: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211:90-98, 1994
14. Yu D, Jing T, Liu B, et al: Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 2:581-591, 1998
15. Sheaff RJ, Singer JD, Swanger J, et al: Proteasoma1 turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol Cell 5:403-410, 2000
16. Asada M, Yamada T, Ichijo H, et al: Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 18:1223-1234, 1999
17. Porter AG: Protein translocation in apoptosis. Trends Cell Biol 9:394-401, 1999
18. Chen J, Jackson PK, Kirschner MW, et al: Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374:386-388, 1995
19. Zhou BP, Liao Y, Xia W, et al: Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3:245-252, 2001
20. Yang HY, Zhou BP, Hung MC, et al: Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J Biol Chem 275:24735-24739, 2000
21. Lenferink AE, Busse D, Flanagan WM, et al: ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res 61:6583-6591, 2001
22. Newman L, Xia W, Yang HY, et al: Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol Carcinog 30:169-175, 2001
23. Woods DB, Vousden KH: Regulation of p53 function. Exp Cell Res 264:56-66, 2001
24. Sherr CJ, Weber JD: The ARF/p53 pathway. Curr Opin Genet Dev 10:94-99, 2000
25. Vousden KH: p53: Death star. Cell 103:691-694, 2000
26. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 408:307-310, 2000
27. Hupp TR, Lane DP, Ball KL: Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J 352:1-17, 2000
28. Caspari T: How to activate p53. Curr Biol 10:R315-R317, 2000
29. Momand J, Wu HH, Dasgupta G: MDM2 - Master regulator of the p53 tumor suppressor protein. Gene 242:15-29, 2000
30. Lill NL, Grossman SR, Ginsberg D, et al: Binding and modulation of p53 by p300/CBP coactivators. Nature 387:823-827, 1997
31. Grossman SR, Perez M, Kung AL, et al: p300/MDM2 complexes participate in MDM2- mediated p53 degradation. Mol Cell 2:405-415, 1998
32. Sherr CJ: The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2:731-737, 2001
33. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al: The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723, 1998
34. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734, 1998
35. Zhang Y, Xiong Y: Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell 3:579-591, 1999
36. Honda R, Yasuda H: Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18:22-27, 1999
37. Weber JD, Taylor LJ, Roussel MF, et al: Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1:20-26, 1999
38. Sabbatini P, McCormick F: Phosphoinositide 3-OH kinase (PI3K) and PKB/ Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis. J Biol Chem 274:24263-24269, 1999
39. Yu D, Hung MC: Role of erbB2 in breast cancer chemosensitivity. Bioessays 22:673-680, 2000
40. Zhou BP, Hu MC, Miller SA, et al: HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275:8027-8031, 2000
41. Zhou BP, Liao Y, Xia W, et al: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3:973-982, 2001
42. Mayo LD, Donner DB: A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 98:11598-11603, 2001
43. Gottlieb TM, Leal JF, Seger R, et al: Cross-talk between Akt, p53 and Mdm2: Possible implications for the regulation of apoptosis. Oncogene 21:1299-1303, 2002
44. Ashcroft M, Ludwig RL, Woods DB, et al: Phosphorylation of HDM2 by Akt. Oncogene 21:1955-1962, 2002
45. Ogawara Y, Kishishita S, Obata T, et al: Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 277:21843-21850, 2002
46. Lin HK, Wang L, Hu YC, et al: Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 21:4037-4048, 2002
47. Simpson L, Parsons R: PTEN: Life as a tumor suppressor. Exp Cell Res 264:29-41, 2001
48. Mayo LD, Dixon JE, Durden DL, et al: PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277:5484-5489, 2002
49. Stambolic V, MacPherson D, Sas D, et al: Regulation of PTEN transcription by p53. Mol Cell 8:317-325, 2001
50. Polakis P: The oncogenic activation of beta-catenin. Curr Opin Genet Dev 9:15-21, 1999
51. Lickert H, Bauer A, Kemler R, et al: Casein kinase II phosphorylation of E-cadherin increases E-cadherin/beta-catenin interaction and strengthens cell-cell adhesion. J Biol Chem 275:5090-5095, 2000
52. He TC, Sparks AB, Rago C, et al: Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512, 1998
53. Tetsu O, McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426, 1999
54. Lin SY, Xia W, Wang JC, et al: Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 97:4262-4266, 2000
55. Su F, Overholtzer M, Besser D, et al: WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. Genes Dev 16:46-57, 2002
56. Grothey A, Hashizume R, Ji H, et al: C-erbB-2/HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene 19:4864-4875, 2000
57. Lejeune S, Huguet EL, Hamby A, et al: Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin Cancer Res 1:215-222, 1995
58. Dale TC, Weber-Hall SJ, Smith K, et al: Compartment switching of WNT-2 expression in human breast tumors. Cancer Res 56:4320-4323, 1996
59. Bui TD, Rankin J, Smith K, et al: A novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas. Oncogene 14:1249-1253, 1997
60. Schroeder JA, Adriance MC, McConnell EJ, et al: ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV), Wnt-1 and MMTV-c-Neu transgenic carcinomas. J Biol Chem 277:22692-22698, 2002
61. Baldwin AS Jr: Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 107:3-6, 2001
62. Mayo MW, Baldwin AS: The transcription factor NF-kappaB: Control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 1470:M55-M62, 2000
63. Cogswell PC, Guttridge DC, Funkhouser WK, et al: Elective activation of NF-kappa B subunits in human breast cancer: Potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 19:1123-1131, 2000
64. Sovak MA, Bellas RE, Kim DW, et al: Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100:2952-2960, 1997
65. Nakshatri H, Bhat-Nakshatri P, Martin DA, et al: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17: 3629-3639, 1997
66. Cao Y, Bonizzi G, Seagroves TN, et al: IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107:763-775, 2001
67. Bhat-Nakshatri P, Sweeney CJ, Nakshatri H: Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene 21: 2066-2078, 2002
68. Biswas DK, Cruz AP, Gansberger E, et al: Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A 97: 8542-8547, 2000
69. Pianetti S, Arsura M, Romieu-Mourez R, et al: Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 20:1287-1299, 2001
70. Madrid LV, Wang CY, Guttridge DC, et al: Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol 20:1626-1638, 2000
71. Madrid LV, Mayo MW, Reuther JY, et al: Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 276:18934-18940, 2001
72. Mayo MW, Madrid LV, Westerheide SD, et al: PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J Biol Chem 277:11116-11125, 2002
73. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
74. Sliwkowski MX, Lofgren JA, Lewis GD, et al: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26:60-70, 1999 (suppl 12)
75. Clynes RA, Towers TL, Presta LG, et al: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446, 2000
76. Cuello M, Ettenberg SA, Clark AS, et al: Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61:4892-4900, 2001
77. Yarden Y: The EGFR family and its ligands in human cancer signalling mechanisms and therapeutic opportunities. Eur J Cancer 37:S3-S8, 2001 (suppl 4)
78. Oved S, Yarden Y: Signal transduction: molecular ticket to enter cells. Nature 416:133-136, 2002
79. Levkowitz G, Klapper LN, Tzahar E, et al: Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene 12:1117-1125, 1996
80. Levkowitz G, Waterman H, Ettenberg SA, et al: Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4:1029-1040, 1999
81. Levkowitz G, Oved S, Klapper LN, et al: c-Cbl is a suppressor of the neu oncogene. J Biol Chem 275:35532-35539, 2000
82. Chiang YJ, Kole HK, Brown K, et al: Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403:216-220, 2000
83. Bachmaier K, Krawczyk C, Kozieradzki I, et al: Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403:211-216, 2000
84. Murphy MA, Schnall RG, Venter DJ, et al: Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol Cell Biol 18:4872-4882, 1998
85. Naramura M, Kole HK, Hu RJ, et al: Altered thymic positive selection and intracellular signals in Cbl-deficient mice. Proc Natl Acad Sci U S A 95:15547-15552, 1998
86. Yarden Y: Biology of HER2 and its importance in breast cancer. Oncology 61:1-13, 2001 (suppl 2)
87. Ettenberg SA, Magnifico A, Cuello M, et al: Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J Biol Chem 276:27677-27684, 2001
88. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002
89. Cho HS, Leahy DJ: Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297:1330-1333, 2002
90. Yu D, Suen TC, Yan DH, et al: Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci U S A 87:4499-4503, 1990
91. Chang JY, Xia W, Shao R, et al: The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene 14:561-568, 1997
92. Ueno NT, Yu D, Hung MC: Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 15:953-960, 1997
93. Shao R, Karunagaran D, Zhou BP, et al: Inhibition of nuclear factor-kappaB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. J Biol Chem 272: 32739-32742, 1997
94. Shao R, Hu MC, Zhou BP, et al: E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IkappaB kinases and nuclear factor kappaB activities. J Biol Chem 274:21495-21498, 1999
95. Lee WP, Wen Y, Varnum B, et al: Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. Oncogene 21:329-336, 2002
96. Hortobagyi GN, Hung MC, Lopez-Berestein G: A phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. Hum Gene Ther 9:1775-1798, 1998
97. Hortobagyi GN, Ueno NT, Xia W, et al: Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial. J Clin Oncol 19:3422-3433, 2001
98. Deng J, Xia W, Hung MC: Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo. Oncogene 17:2167-2175, 1998
99. Deng J, Kloosterbooer F, Xia W, et al: The NH(2)-terminal and conserved region 2 domains of adenovirus E1A mediate two distinct mechanisms of tumor suppression. Cancer Res 62:346-350, 2002
100. Citri A, Alroy I, Lavi S, et al: Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: Implications for cancer therapy. EMBO J 21:2407-2417, 2002
101. Zhang L, Lau YK, Xi L, et al: Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene 16:2855-2863, 1998
102. Zhang L, Lau YK, Xia W, et al: Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res 5:343-353, 1999
103. Xing X, Wang SC, Xia W, et al: The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med 6:189-195, 2000
104. Wang SC, Hung MC: HER2 overexpression and cancer targeting. Semin Oncol 28:115-124, 2001 (suppl 16)
105. Wang SC, Zhang L, Hortobagyi GN, et al: Targeting HER2: recent developments and future directions for breast cancer patients. Semin Oncol 28:21-29, 2001 (suppl 18)
106. Batra RK, Guttridge DC, Brenner DA, et al: Ikappa-Balpha gene transfer is cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-alpha-mediated cell death. Am J Respir Cell Mol Biol 21:238-245, 1999
107. Keane MM, Rubinstein Y, Cuello M, et al: Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res Treat 64:211-219, 2000